Verici Dx Plc announced positive progress in its plans to drive strong Tutiviatm sales growth following the equity fundraise completed in July. Commercial scale-up of Tutiviatm test adoption, a test for acute rejection post transplant, has progressed in third quarter, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from fourth quarter and the number of orders in third quarter were consistent with the previous two quarters.
The Company has expanded its commercial team with three new senior sales hires. In addition, a Director of Clinical Partnerships will be joining the commercial team in mid-October. The Board continues to target meeting market expectations for the full year.
